title: Agaricus bisporus fucogalactan: structural characterization and pharmacological approaches.
abstract: The fucogalactan from Agaricus bisporus (EFP-Ab) obtained on aqueous extraction followed by purification had M(w) 37.1 × 10(4)g mol(-1) relative to a (1→6)-linked α-D-Galp main-chain partially methylated at HO-3, and partially substituted at O-2 by nonreducing end-units of α-L-Fucp or β-d-Galp. EFP-Ab also inhibited significantly the neurogenic and inflammatory phases of formalin-induced licking, however, the antinociceptive effect was more pronounced against the inflammatory phase with ID(50) of 36.0 (25.8-50.3)mg kg(-1). In addition, EFP-Ab decreased the lethality induced by CLP. Its administration reduced the late mortality rate by 40%, prevented neutrophil accumulation in lungs and markedly decreased iNOS and COX-2 protein expression by ileum cells. These data show for the first time that EFP-Ab has significant anti-sepsis, antinociceptive and anti-inflammatory actions, which seems to be related to the decreased iNOS and COX-2 expression. Collectively, the present results demonstrate that EFP-Ab could constitute an attractive molecule of interest for the development of new drugs.
authors.affiliation: Departamento de Bioquímica e Biologia Molecular, Universidade Federal do Paraná, CP 19046, CEP 81531-980, Curitiba, PR, Brazil.
authors.forename: Andrea C
authors.initials: AC
authors.lastname: Ruthes
authors.forename: Yanna D
authors.initials: YD
authors.lastname: Rattmann
authors.forename: Simone M
authors.initials: SM
authors.lastname: Malquevicz-Paiva
authors.forename: Elaine R
authors.initials: ER
authors.lastname: Carbonero
authors.forename: Marina M
authors.initials: MM
authors.lastname: Córdova
authors.forename: Cristiane H
authors.initials: CH
authors.lastname: Baggio
authors.forename: Adair R S
authors.initials: AR
authors.lastname: Santos
authors.forename: Philip A J
authors.initials: PA
authors.lastname: Gorin
authors.forename: Marcello
authors.initials: M
authors.lastname: Iacomini
mesh_terms: D000364:Agaricus / Q000737:chemistry*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000302:isolation & purification / Q000493:pharmacokinetics; D051546:Cyclooxygenase 2 / Q000378:metabolism; D005557:Formaldehyde / Q000633:toxicity; D062610:Fungal Polysaccharides / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D005685:Galactans / Q000737:chemistry / Q000302:isolation & purification / Q000493:pharmacokinetics; D006801:Humans; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy; D051379:Mice; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy
chemical_list: D000893:Anti-Inflammatory Agents; D062610:Fungal Polysaccharides; D005685:Galactans; D005557:Formaldehyde; C031159:fucogalactan; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2